

ATTORNEY DOCKET NO. 14014.0312  
PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of )  
Kelsall et al. )  
Serial No. 09/196,867 ) Group Art Unit: 1644  
Filed: November 20, 1998 ) Examiner: DeCloux, A. #8  
P.J.J  
11/29/99  
For: METHODS OF USING CR3 AND CR4 )  
LIGANDS FOR INHIBITING )  
INTERLEUKIN-12 TO TREAT )  
AUTOIMMUNE DISEASE )

RECEIVED  
NOV 16 1999  
GROUP 1800

ELECTION UNDER RESTRICTION REQUIREMENTVIA FACSIMILE TRANSMISSION703/305-3704

ATTN: Examiner A. DeCloux  
Group Art Unit 1644  
Assistant Commissioner for Patents  
Washington, D.C. 20231

NEEDLE & ROSENBERG, P.C.  
Suite 1200, The Candler Building  
127 Peachtree Street, N.E.  
Atlanta, Georgia 30303-1811

November 15, 1999

Sir:

This is in response to the Office Action dated September 17, 1999, wherein restriction of the claims of the above-identified application is required. The Office Action requires restriction to one of the following three groups of claims:

Group I: Claims 1-11, drawn to a method of downregulating IL-12 with CR3/4 ligands.

Group II: Claim 12, drawn to a method of screening a substance for its ability to downregulate IL-12 upon binding CR3.

Group III: Claim 13, drawn to a method of screening a substance for its ability to